Table 1.
Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma after failure of standard chemotherapy (Northfelt et al 1997)
| Best response | All patients (n = 53) | Doxorubicin failurea (n = 28) |
|---|---|---|
| Complete clinical | 1 (2%) | 0 |
| Partial | 19 (36%) | 9 (32%) |
| Stable | 19 (36%) | 14 (50%) |
| Progression | 14 (26%) | 5 (18%) |
| Median time (days) to PR | 109 | 109 |
| Median duration (days) of PR | 128 | 127 |
| Median time (days) to treatment Failure | 134 | 148 |
a
Patients whose AIDS-KS progressed on a combination regimen containing doxorubicin.